glp-1 masld Direct and indirect effects of GLP1‐RA in obesity, T2D and Novel treatment approaches common to

Tirzepatide Tirzepatide is a dual GLP-1/GIP receptor agonist

C., & Stefanski, A

In addition to their established benefits for the management of diabetes and obesity, GLP-1RAs have shown potential in managing MASLD through mechanisms such as reducing hepatic lipogenesis, improving insulin sensitivity, and modulating inflammation

For example, liraglutide, though also effective, typically results in somewhat lower overall weight loss than semaglutide, with dulaglutide and exenatide demonstrating similarly modest outcomes by comparison

The SUMMIT study assesses tirzepatides impact on HF with HFpEF in obese patients

Do this first thing in the morning or before attempting a bowel movement